New Jersey-New York 7 Conference

Bayer Fund Awards More than $13M to U.S. Nonprofit Organizations in 2022, Following Latest Round of Grants Totaling $5.2M

Retrieved on: 
Thursday, March 2, 2023

This latest round of grants raised Bayer Fund’s 2022 giving total to more than $13.4 million across 2,700 charitable and nonprofit organizations to help address essential needs in Food and Nutrition, STEM Education and Health & Wellness.

Key Points: 
  • This latest round of grants raised Bayer Fund’s 2022 giving total to more than $13.4 million across 2,700 charitable and nonprofit organizations to help address essential needs in Food and Nutrition, STEM Education and Health & Wellness.
  • Bayer Fund is excited to give back to communities by providing funding that helps strengthen organizations through impactful programs that align with our primary giving priorities,” said Al Mitchell, President of Bayer Fund.
  • Pittsburgh, PA-based 412 Food Rescue was awarded $50,000 in grant funding to support its Good Food Project.
  • The organization’s mission is to prevent food from unnecessarily being wasted, redirecting it to those experiencing food insecurity.

Practice Changing Study Highlights Value of Starting Immunotherapy Before Targeted Therapies in Patients with BRAF-Mutated Melanoma

Retrieved on: 
Tuesday, October 4, 2022

Targeted medications and immunotherapy have become standard care for people with advanced melanoma.

Key Points: 
  • Targeted medications and immunotherapy have become standard care for people with advanced melanoma.
  • Starting in 2015, 265 patients with metastatic melanoma were randomly assigned to one of two groups.
  • One group started treatment with combination ipilimumab and nivolumab immunotherapy, and the second group began with the targeted therapies dabrafenib and trametinib.
  • Two-year overall survival was 72% among patients who received combination immunotherapy first versus 52% for those who took the two targeted therapies as initial treatment.

Benefit of Adding Ibrutinib to Bendamustine/Rituximab as Frontline Treatment for Mantle Cell Lymphoma: First Phase III Trial Changing the Paradigm for the Care of Elderly Patients

Retrieved on: 
Friday, June 3, 2022

HACKENSACK, N.J., June 3, 2022 /PRNewswire/ -- Hackensack Meridian John Theurer Cancer Center investigators participated in the large phase III multicenter SHINE study, which reported that using the drug ibrutinib (Imbruvica®) in combination with standard bendamustine and rituximab (BR) therapy as initial treatment for mantle cell lymphoma (MCL) slowed disease growth by 52% in older people newly diagnosed with the disease. The treatment could become the new standard of care for older people with MCL, who may not be able to tolerate more intensive treatment regimens. The study was published in the New England Journal of Medicine on June 3, 2022.

Key Points: 
  • The treatment could become the new standard of care for older people with MCL, who may not be able to tolerate more intensive treatment regimens.
  • "The field of mantle cell lymphoma treatment continues to evolve.
  • Logically, the next step was to bring it to the frontline setting, which was the subject of the SHINE clinical trial."
  • John Theurer Cancer Center is a part of the Georgetown Lombardi Comprehensive Cancer Center, an NCI-designated Comprehensive Cancer Center.

The Institute for Reproductive Medicine & Science (IRMS) is proud to welcome Dr. Melissa Yih to their Staten Island practice

Retrieved on: 
Tuesday, October 19, 2021

STATEN ISLAND, N.Y., Oct. 19, 2021 /PRNewswire/ --The Institute for Reproductive Medicine & Science (IRMS) is thrilled to announce that Melissa C. Yih, MD has joined their practice and will head their new, state-of-the-art location in Staten Island.

Key Points: 
  • STATEN ISLAND, N.Y., Oct. 19, 2021 /PRNewswire/ --The Institute for Reproductive Medicine & Science (IRMS) is thrilled to announce that Melissa C. Yih, MD has joined their practice and will head their new, state-of-the-art location in Staten Island.
  • "Dr. Yih brings a tremendous amount of experience to our clinical practice and our valued IRMS patients."
  • (Debbra A. Keegan, MD Clinical Director IRMS)
    Dr. Yih is Board Certified in both Obstetrics & Gynecology and Reproductive Endocrinology and Infertility and has been practicing since 2002.
  • Dr. Yih is excited to see patients in our Staten Island office, as well as, offering convenient telemedicine appointments.

Hackensack University Medical Center and the John Theurer Cancer Center Ranked One of Newsweek's World's Best Specialized Hospitals

Retrieved on: 
Thursday, October 7, 2021

HACKENSACK, N.J., Oct. 7, 2021 /PRNewswire/ -- Hackensack Meridian's Hackensack University Medical Center and its John Theurer Cancer Center has again ranked among the top hospitals in the Newsweek's 2022 World's Best Specialized Hospitals list.

Key Points: 
  • HACKENSACK, N.J., Oct. 7, 2021 /PRNewswire/ -- Hackensack Meridian's Hackensack University Medical Center and its John Theurer Cancer Center has again ranked among the top hospitals in the Newsweek's 2022 World's Best Specialized Hospitals list.
  • "I am immensely proud that John Theurer Cancer Center is recognized as one of World's Best Specialized Hospitalsby Newsweek," said Andre Goy, M.D., M.S., chairman and executive director of John Theurer Cancer Center.
  • John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's best cancer center, as recognized by U.S. News & World Report.
  • John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center, an NCI designated comprehensive cancer center.